Effective November 01, 2024: Please see North London NHS Foundation Trust.
Camden and Islington NHS Foundation Trust has received £49,838,776 from 1 department.
We currently have no contracts recorded for Camden and Islington NHS Foundation Trust.
A breakdown of the top government departments that have purchased goods and services from Camden and Islington NHS Foundation Trust, ordered by total spend.
£49.8 Million
A breakdown of the top government organisations that have purchased goods and services from Camden and Islington NHS Foundation Trust, ordered by total spend. These may be more granular than departments.
£49.8 Million
A breakdown of the top Expense Areas within each organisation that has purchased goods and services from Camden and Islington NHS Foundation Trust, ordered by total spend.
Department of Health and Social Care - £33.2 Million
Department of Health and Social Care - £6.4 Million
Department of Health and Social Care - £5.08 Million
Department of Health and Social Care - £3.68 Million
Department of Health and Social Care - £950 Thousand
A breakdown of the top Expense Types within each organisation that has purchased goods and services from Camden and Islington NHS Foundation Trust, ordered by total spend.
Department of Health and Social Care - £38.1 Million
Department of Health and Social Care - £16.6 Million
Department of Health and Social Care - £12 Million
Department of Health and Social Care - £840 Thousand
Department of Health and Social Care - £110 Thousand
| Date | Buyer | Amount | Expense Area | Expense Type | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-25 | £190,352 | Chief Scientific Adviser | Research & development | ||||||||
| HTA Pharmaceuticals and Gene Therapy | |||||||||||
| 2024-09-25 | £112,122 | Chief Scientific Adviser | Research & development | ||||||||
| Programme Grants (PG) | |||||||||||
| 2024-09-25 | £158,642 | Chief Scientific Adviser | Research & development | ||||||||
| HTA Pharmaceuticals and Gene Therapy | |||||||||||
| 2024-09-25 | £48,946 | Chief Scientific Adviser | Research & development | ||||||||
| HTA Other Therapeutic Interventions | |||||||||||
| 2024-09-25 | £53,526 | Chief Scientific Adviser | Research & development | ||||||||
| Health Services and Delivery Research | |||||||||||
| 2024-09-25 | £115,836 | Chief Scientific Adviser | Research & development | ||||||||
| HTA Other Therapeutic Interventions | |||||||||||
| 2024-09-25 | £225,490 | Chief Scientific Adviser | Research & development | ||||||||
| Research Capability Funding - Standard | |||||||||||
| 2024-09-25 | £47,380 | Chief Scientific Adviser | Research & development | ||||||||
| Programme Grants (PG) | |||||||||||
| 2024-09-16 | -£721,158 | Finance | Interest Receivable NCB Loan | ||||||||
| Interest Receivable NCB Loan | |||||||||||
| 2024-09-16 | -£3,157,000 | Finance | Dividends receivable on PDC | ||||||||
| Dividends receivable on PDC | |||||||||||
| 2024-07-15 | £975,000 | Finance | Additions NCB PDC | ||||||||
| Additions NCB PDC | |||||||||||
| 2024-06-25 | £190,352 | Chief Scientific Adviser | Research & development | ||||||||
| HTA Pharmaceuticals and Gene Therapy | |||||||||||
| 2024-06-25 | £133,185 | Chief Scientific Adviser | Research & development | ||||||||
| Programme Grants (PG) | |||||||||||
| 2024-06-25 | £161,848 | Chief Scientific Adviser | Research & development | ||||||||
| HTA Pharmaceuticals and Gene Therapy | |||||||||||
| 2024-06-25 | £83,262 | Chief Scientific Adviser | Research & development | ||||||||
| HTA Other Therapeutic Interventions | |||||||||||
| 2024-06-25 | £49,601 | Chief Scientific Adviser | Research & development | ||||||||
| Health Services and Delivery Research | |||||||||||
| 2024-06-25 | £198,458 | Chief Scientific Adviser | Research & development | ||||||||
| HTA Other Therapeutic Interventions | |||||||||||
| 2024-06-25 | £225,490 | Chief Scientific Adviser | Research & development | ||||||||
| Research Capability Funding - Standard | |||||||||||
| 2024-06-25 | £27,191 | Chief Scientific Adviser | Research & development | ||||||||
| HTA Other Therapeutic Interventions | |||||||||||
| 2024-06-25 | £125,623 | Chief Scientific Adviser | Research & development | ||||||||
| Programme Grants (PG) | |||||||||||
Showing 1 to 20 of 156 transactions
The most recent payment data we have available for Camden and Islington NHS Foundation Trust is from September 2024. Government departments and public bodies typically publish their spending data on a monthly or quarterly basis.
Camden and Islington NHS Foundation Trust's government income has decreased over time. In 2024, they received £7,154,609, compared to £31,666,076 in 2023 - a decrease of 77.4%.
Camden and Islington NHS Foundation Trust has received a total of £49,838,776 from UK government organizations according to our records. This income comes from 1 government buyer.
The primary government buyer from Camden and Islington NHS Foundation Trust is Department of Health and Social Care, which has spent £49,838,777.